查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600972

感染疾病體外診斷市場：按產品、技術、適應症和最終用戶分類 - 2025-2030 年全球預測

Infectious Diseases In-Vitro Diagnostics Market by Product (Instruments, Reagents, Software), Technology (Immunochemistry, Microbiology, Molecular Diagnostics), Indication, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，感染疾病體外診斷市值為490.6億美元，預計到2024年將達到525.1億美元，複合年成長率為7.22%，到2030年將達到799.5億美元。

感染疾病體外診斷（IVD）市場範圍包括對血液、組織和其他體液等樣本進行診斷測試，以檢測人體內的感染疾病。由於全球感染疾病爆發次數不斷增加、對快速診斷解決方案的需求不斷增加以及 COVID-19 等流行病的持續威脅，該市場變得至關重要。這些診斷對於及時、準確的診斷、促進適當的治療計劃和管理、從而挽救生命和減少疾病傳播至關重要。最終用途包括檢測愛滋病毒、流感、結核病、肝炎、新興感染疾病等，並包括醫院、臨床實驗室和照護現場。市場成長受到次世代定序、PCR 和免疫測量等技術進步的顯著影響，這些技術進步提高了準確性和速度。利用人工智慧和機器學習來解釋診斷結果的新穎用途也帶來了顯著的機會。此外，在便利性、結果即時解釋和隱私的推動下，人們對家庭測試的日益重視，正在該行業中開闢出一個重要的利基市場。然而，先進診斷技術的高價格、監管障礙以及新興市場有限的醫療基礎設施等挑戰正在限制市場擴張。由於某些測試中的技術限制而導致的不可靠結果也可能成為阻礙力。技術創新的關鍵領域是開發價格實惠、簡單且高度靈敏的攜帶式診斷儀。此類創新可以大大提高可及性，尤其是在世界資源匱乏的環境中。此外，尋找新疾病的生物標記以及同時針對多種病原體的多重測試的擴展可能會改變遊戲規則。隨著新的傳染性威脅的頻繁出現，這個市場的性質是高度動態的，需要技術提供者和醫療保健專業人員之間持續的研究和開發投資以及合作，以保持熟練的應對力。利用市場機會的建議包括策略夥伴關係和對研發的大力投資，以開發更有效、更便宜的診斷方法。

主要市場統計
基準年[2023] 490.6億美元
預測年份 [2024] 525.1億美元
預測年份 [2030] 799.5億美元
複合年成長率（%） 7.22%

市場動態：快速發展的感染疾病體外診斷市場的關鍵市場洞察

感染疾病體外診斷市場正因供需之間的動態互動而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 感染疾病流行不斷增加和週期性爆發
    • 更多採用快速檢測套組進行感染疾病診斷
    • 實施政府舉措抑制病毒性疾病
  • 市場限制因素
    • 召回感染疾病體外診斷藥物
  • 市場機會
    • 基因組學和蛋白​​質組學的進展
    • 增加研發投資推出新的體外診斷
  • 市場挑戰
    • 感染疾病體外診斷試劑套件的供應有限

波特五力：引領感染疾病體外診斷市場的策略工具

波特的五力架構是了解感染疾病體外診斷市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對感染疾病體外診斷市場的影響

外部宏觀環境因素在塑造感染疾病體外診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解感染疾病體外診斷市場的競爭狀況

對感染疾病體外診斷市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣感染疾病體外診斷市場供應商績效評估

FPNV定位矩陣是評估感染疾病體外診斷市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病和週期性流行病的傳播增加
      • 增加引進用於診斷感染疾病的快速檢測套組
      • 實施政府控制病毒性疾病的舉措
    • 抑制因素
      • 召回感染疾病體外診斷產品
    • 機會
      • 基因組學和蛋白​​質組學的進展
      • 加大研發投入，推出新的IVD產品
    • 任務
      • 感染疾病體外診斷試劑套件准入限制
  • 市場區隔分析
    • 產品：對檢測傳染性病原體的先進試劑的需求不斷成長
    • 技術：擴大分子診斷技術的採用，以快速檢測和量化愛滋病毒和肝炎感染等病毒量
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章感染疾病體外診斷市場：依產品

  • 裝置
  • 試劑
  • 軟體

第7章感染疾病體外診斷市場：依技術分類

  • 免疫化學
  • 微生物學
  • 分子診斷

第8章感染疾病體外診斷市場（依適應症）

  • 念珠菌症
  • 披衣菌感染
  • 困難梭狀芽孢桿菌
  • 創新的
  • 胃腸炎
  • 淋病
  • 肝炎
  • HIV
  • HPV
  • MRSA
  • 呼吸道病毒
  • 鏈球菌
  • 結核病和抗藥性結核病
  • ＶＲＥ

第9章感染疾病體外診斷市場：依最終用戶分類

  • 學術研究所
  • 診斷實驗室
  • 醫院/診所

第10章 南北美洲感染疾病體外診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區感染疾病體外診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東、非洲感染疾病體外診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 羅氏推出下一代 QPCR 系統，以改善臨床需求並應對分子診斷的公共衛生挑戰
    • Biocare Medical 宣布推出新型 IVD 抗原修復室 ARC，用於可靠、準確且一致的熱誘導表位修復 (HIER)
    • 推出免疫組織化學新試劑解決方案“Optimer-Fc”
    • DxLab 在烤麵包機大小的盒子中提供實驗室品質的感染疾病和有害病原體檢測

公司名單

  • Trinity Biotech PLC
  • Qiagen NV
  • DiaSorin SpA
  • Koninklijke Philips NV
  • Vela Diagnostics
  • InBios International, Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics
  • F. Hoffmann La-Roche Ltd.
  • bioMerieux SA
  • Laboratory Corporation Of America Holdings
  • Sysmex Corporation
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Grifols, SA
  • Hologic, Inc.
  • Siemens Healthineers AG
  • Danaher Corporation
  • Quidel Corporation
  • Epitope Diagnostics, Inc.
  • Genspeed Biotech GmbH
  • Meril Life Sciences Pvt. Ltd.
  • Abbott Laboratories
  • Uniogen Oy
  • DX Lab Inc.
  • Illumina, Inc.
  • OraSure Technologies, Inc.
  • Merck KGaA
  • Becton, Dickinson and Company
Product Code: MRR-A339DAEFAD44

The Infectious Diseases In-Vitro Diagnostics Market was valued at USD 49.06 billion in 2023, expected to reach USD 52.51 billion in 2024, and is projected to grow at a CAGR of 7.22%, to USD 79.95 billion by 2030.

The scope of the infectious diseases in-vitro diagnostics (IVD) market encompasses diagnostic tests performed on samples such as blood, tissue, and other body fluids to detect infectious diseases within the human body. This market has become essential due to rising global infectious disease prevalence, increasing demand for rapid diagnostic solutions, and the ongoing threat of pandemics like COVID-19. These diagnostics are imperative for timely and accurate diagnosis, facilitating proper treatment plans and management, thus saving lives and curbing disease spread. Key applications involve testing for diseases such as HIV, influenza, tuberculosis, hepatitis, and emerging infections, with end-use sectors including hospitals, clinical laboratories, and point-of-care settings. Market growth is significantly influenced by technological advancements like next-generation sequencing, PCR, and immunoassays leading to improved accuracy and speed. The novel use of AI and machine learning for interpreting diagnostic results also presents noteworthy opportunities. Furthermore, the growing emphasis on home testing, fueled by convenience, immediate result interpretation, and privacy, is carving a significant niche within this industry. However, challenges such as high costs of advanced diagnostics, regulatory hurdles, and limited healthcare infrastructure in developing regions restrain market expansion. Also, unreliable results due to technical limitations in specific tests can be a deterrent. A key area for innovation lies in the development of affordable, simple, yet highly sensitive portable diagnostics. These innovations can dramatically enhance accessibility, particularly in low-resource settings worldwide. Also, exploring biomarkers for novel diseases and expanding multiplex testing, which simultaneously targets multiple pathogens, can be game-changers. The nature of this market is highly dynamic, driven by the frequent emergence of new infectious threats, thus requiring continuous R&D investment and collaboration between technology providers and healthcare professionals to stay adept and responsive. Recommendations for capitalizing on market opportunities include strategic partnerships and robust investments in R&D to cultivate more effective, less expensive diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 49.06 billion
Estimated Year [2024] USD 52.51 billion
Forecast Year [2030] USD 79.95 billion
CAGR (%) 7.22%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Diseases In-Vitro Diagnostics Market

The Infectious Diseases In-Vitro Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Prevalence and Periodic Outbreak of Infectious Diseases
    • Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
    • Implementation of Government Initiatives to Curb Viral Diseases
  • Market Restraints
    • Product Recalls of Infectious Disease In-vitro Diagnostics
  • Market Opportunities
    • Advancements in Genomics and Proteomics
    • Increasing Investments in R&D to Launch New IVD Products
  • Market Challenges
    • Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Diseases In-Vitro Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Diseases In-Vitro Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Diseases In-Vitro Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Diseases In-Vitro Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Diseases In-Vitro Diagnostics Market

A detailed market share analysis in the Infectious Diseases In-Vitro Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Diseases In-Vitro Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Diseases In-Vitro Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Infectious Diseases In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Trinity Biotech PLC, Qiagen N.V., DiaSorin S.p.A, Koninklijke Philips N.V., Vela Diagnostics, InBios International, Inc., PerkinElmer, Inc., Quest Diagnostics, F. Hoffmann La-Roche Ltd., bioMerieux SA, Laboratory Corporation Of America Holdings, Sysmex Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Grifols, S.A., Hologic, Inc., Siemens Healthineers AG, Danaher Corporation, Quidel Corporation, Epitope Diagnostics, Inc., Genspeed Biotech GmbH, Meril Life Sciences Pvt. Ltd., Abbott Laboratories, Uniogen Oy, DX Lab Inc., Illumina, Inc., OraSure Technologies, Inc., Merck KGaA, and Becton, Dickinson and Company.

Market Segmentation & Coverage

This research report categorizes the Infectious Diseases In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instruments, Reagents, and Software.
  • Based on Technology, market is studied across Immunochemistry, Microbiology, and Molecular Diagnostics.
  • Based on Indication, market is studied across Candidiasis, Chlamydia, Clostridium difficile, CRE, Gastroenteritis, Gonorrhea, Hepatitis, HIV, HPV, MRSA, Respiratory Virus, Streptococcus, TB and Drug-resistant TB, and VRE.
  • Based on End-user, market is studied across Academic Research Institutes, Diagnostic Laboratories, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence and Periodic Outbreak of Infectious Diseases
      • 5.1.1.2. Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
      • 5.1.1.3. Implementation of Government Initiatives to Curb Viral Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Product Recalls of Infectious Disease In-vitro Diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Genomics and Proteomics
      • 5.1.3.2. Increasing Investments in R&D to Launch New IVD Products
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising demand for advanced reagents for testing infectious pathogens
    • 5.2.2. Technology: Expanding adoption of molecular diagnostics technology to quickly detect and quantify viral load, such as in HIV or hepatitis infections
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Infectious Diseases In-Vitro Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents
  • 6.4. Software

7. Infectious Diseases In-Vitro Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Immunochemistry
  • 7.3. Microbiology
  • 7.4. Molecular Diagnostics

8. Infectious Diseases In-Vitro Diagnostics Market, by Indication

  • 8.1. Introduction
  • 8.2. Candidiasis
  • 8.3. Chlamydia
  • 8.4. Clostridium difficile
  • 8.5. CRE
  • 8.6. Gastroenteritis
  • 8.7. Gonorrhea
  • 8.8. Hepatitis
  • 8.9. HIV
  • 8.10. HPV
  • 8.11. MRSA
  • 8.12. Respiratory Virus
  • 8.13. Streptococcus
  • 8.14. TB and Drug-resistant TB
  • 8.15. VRE

9. Infectious Diseases In-Vitro Diagnostics Market, by End-user

  • 9.1. Introduction
  • 9.2. Academic Research Institutes
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Clinics

10. Americas Infectious Diseases In-Vitro Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Infectious Diseases In-Vitro Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Infectious Diseases In-Vitro Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Roche Launches Next-Generation Qpcr System to Advance Clinical Needs In Molecular Diagnostics and Address Public Health Challenges
    • 13.3.2. Biocare Medical Announces the Launch of ARC: The New IVD Antigen Retrieval Chamber for Reliable, Precise and Consistent Heat Induced Epitope Retrieval (HIER)
    • 13.3.3. Launch of Optimer-Fc as a New Reagent Solution for Immunohistochemistry
    • 13.3.4. DxLab Delivers Lab-Quality Detection of Infectious Diseases and Harmful Pathogens in a Toaster-Size Box

Companies Mentioned

  • 1. Trinity Biotech PLC
  • 2. Qiagen N.V.
  • 3. DiaSorin S.p.A
  • 4. Koninklijke Philips N.V.
  • 5. Vela Diagnostics
  • 6. InBios International, Inc.
  • 7. PerkinElmer, Inc.
  • 8. Quest Diagnostics
  • 9. F. Hoffmann La-Roche Ltd.
  • 10. bioMerieux SA
  • 11. Laboratory Corporation Of America Holdings
  • 12. Sysmex Corporation
  • 13. Bio-Rad Laboratories, Inc.
  • 14. Thermo Fisher Scientific Inc.
  • 15. Grifols, S.A.
  • 16. Hologic, Inc.
  • 17. Siemens Healthineers AG
  • 18. Danaher Corporation
  • 19. Quidel Corporation
  • 20. Epitope Diagnostics, Inc.
  • 21. Genspeed Biotech GmbH
  • 22. Meril Life Sciences Pvt. Ltd.
  • 23. Abbott Laboratories
  • 24. Uniogen Oy
  • 25. DX Lab Inc.
  • 26. Illumina, Inc.
  • 27. OraSure Technologies, Inc.
  • 28. Merck KGaA
  • 29. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CRE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GASTROENTERITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HPV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MRSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY RESPIRATORY VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STREPTOCOCCUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TB AND DRUG-RESISTANT TB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VRE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. NIGERIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. NORWAY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. POLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. QATAR INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SAUDI ARABIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. SWEDEN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. SWITZERLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. TURKEY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED ARAB EMIRATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 203. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023